Transdermal Drug Delivery: Clinical Considerations for the Obstetrician–Gynecologist

@article{Potts2005TransdermalDD,
  title={Transdermal Drug Delivery: Clinical Considerations for the Obstetrician–Gynecologist},
  author={R. Potts and R. Lobo},
  journal={Obstetrics & Gynecology},
  year={2005},
  volume={105},
  pages={953-961}
}
  • R. Potts, R. Lobo
  • Published 2005
  • Medicine
  • Obstetrics & Gynecology
  • INTRODUCTION: The first transdermal drug delivery system was introduced in the United States over 20 years ago. Created as an alternative route of administration to improve patient compliance as well as to reduce side effects, the transdermal delivery of drugs now represents a $1.5 to $2 billion market and is growing rapidly. DATA SOURCES: The medical literature from 1980 to 2005 was searched using the PubMed search engine. The search term was “transdermal,” limited to human clinical trials… CONTINUE READING
    28 Citations
    Transdermal hormonal contraception: benefits and risks.
    • R. Burkman
    • Medicine
    • American journal of obstetrics and gynecology
    • 2007
    • 50
    Transdermal contraception methods: today’s patches and new options on the horizon
    • A. Nelson
    • Medicine
    • Expert opinion on pharmacotherapy
    • 2015
    • 3
    Transdermal delivery of combined hormonal contraception: a review of the current literature
    • 18
    • PDF
    Transdermal contraceptive patches
    • 3
    Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: In vitro and in vivo characterization.
    • 23

    References

    SHOWING 1-10 OF 41 REFERENCES
    Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler.
    • 243
    • PDF
    Transdermal Drug Transport and Metabolism. I. Comparison of In Vitro and In Vivo Results
    • 51